BioArctic’s business strategy is to build a research portfolio with a number of innovative projects successively reaching a suitable point for entering into partnerships with global pharma companies. Our research and development work is proceeding in line with this strategy.

We have high scientific competence and skills as well as a proven track record of delivering innovative pharmaceutical projects. Collaborations with universities are of great importance to the company together with the strategically important global partners in the Alzheimer and Parkinson projects. BioArctic conducts its own clinical development in the field of complete spinal cord injury. Through long-term collaboration agreements with global pharmaceutical companies, BioArctic has demonstrated high skills and good ability to deliver innovative pharmaceutical projects.

Alzheimer’s disease

Ongoing Phase 2b clinical study with drug candidate BAN2401.

Parkinson’s disease

BioArctic has developed antibodies that can remove or inactivate the toxic forms of alpha-synuclein.

Complete Spinal Cord Injury

We want to develop an innovative treatment that substantially improves the patients’ quality of life.